Status:
UNKNOWN
Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Top Institute Pharma
Collaborating Sponsors:
Academisch Ziekenhuis Maastricht
University Medical Center Groningen
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18-75 years
Brief Summary
COPD is ranked number 3 by the WHO list of important diseases worldwide and is the only disease with increasing mortality. The pathogenesis of cigarette smoke-induced COPD is obscure, therefore more i...
Eligibility Criteria
Inclusion
- Age ≥18 and ≤75 years
- Age, pack years, FEV1/FVC and FEV1% predicted must fit in one of the 9 groups of the study population
- Physically and mentally able to undergo the total study protocol
- Written informed consent
Exclusion
- Participation in another study
- Alpha-1-antitrypsin deficiency
- Selected grade 1-3 co-morbidity listed in the ACE-27
- Active pulmonary infection like tuberculosis, pneumonia, flue, tracheobronchitis
- Active extra-pulmonary infection like hepatitis A-C, cystitis, gastro-enteritis etc
- Pulmonary diseases like sarcoidosis, pulmonary fibrosis, silicosis, hypersensitivity pneumonitis, asthma
- Life threatening diseases like carcinoma, AIDS (including HIV+), acute leukaemia etc
- Medication that may affect the results of the study: NSAID's, immunosuppressive agents like prednisolon, metotrexate, azathioprine
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00850863
Start Date
February 1 2009
End Date
January 1 2015
Last Update
February 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands, 3508GA